Analysis of Status and Risk Factors of Disease Progression in Female Breast Cancer Patients in Liuzhou, China

Abstract

Objective To analyze the current status and disease progression of breast cancer patients in a hospital in Liuzhou, to explore their influencing factors, and to provide reference for breast cancer treatment and prognosis. Methods Patients with primary breast cancer diagnosed in the clinical pathway of a hospital in Liuzhou 2022 were selected as study subjects. The patients were divided into different subgroups by collecting various clinical indicators, comparing and analyzing the differences in lipid and pathological characteristics, and further analyzing the relationship between the observed indicators and disease progression through correlation analysis and logistic regression. Results The 226 breast cancer patients included were aged between 24 and 78 years, with a median age of 50 years, 124 (54.9%) were menopausal and 102 (45.1%) were not. The percentage of patients with body mass index (BMI), blood glucose, and blood pressure at normal levels before treatment were 55.31%, 90.71%, and 71.24%, respectively. Four lipid indices were found: TC: 5.33 ± 1.03 mmol/L, TG: 1.17 (0.73, 1.69) mmol/L, HDL-C: 1.46 ± 0.34 mmol/L, LDL-C: 2.30 (1.60, 3.50) mmol/L. Pathological stage II (46.0%), histology II (75.6%), tumor T2 stage (55.3%), armpit lymph node negative status (62.8%), Luminal B (37.6%), and no disease progression (83.1%) had the highest percentage. The results of the multifaceted analysis showed that molecular typing and pathological staging were risk factors for disease progression in breast cancer patients (OR 3.165, 19.053, Ρ < 0.05, respectively); lipid indexes could not be considered as independent risk factors for disease progression yet (Ρ > 0.05). Conclusion There is no exact correlation between lipid indices and pathological features and disease progression, molecular typing and pathological staging may be relevant risk factors influencing the progression of the disease, and this study provides a basis for personalized treatment and prognosis of breast cancer patients.